CARISMA Therapeutics to Participate in Upcoming Investor Conferences
PHILADELPHIA, Oct. 5, 2020 /PRNewswire/ -- CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at two virtual investor conferences in October 2020.
- Chardan 4th Annual Genetic Medicines ConferenceTuesday, October 6, 2020 at 11:00 am EST
- 7th Solebury Trout Private Company Showcase Co-Hosted by BMO and Davis PolkThursday, October 15, 2020 at 10:40 am EST
About CARISMA Therapeutics Inc.CARISMA Therapeutics Inc. is a biopharmaceutical company developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. CARISMA Therapeutics is headquartered in Philadelphia, PA.
For more information, please visit www.carismatx.com
Media Contact: Christina Khoury-Folkens 612-806-0757 [email protected]
View original content to download multimedia:http://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-upcoming-investor-conferences-301145219.html
SOURCE CARISMA Therapeutics Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Asphalt Expert Robert Stewart Explains Asphalt Driveway Installation Preparation in HelloNation
- Alibaba Group Announced Pricing of HK$80 Billion Placing of New Shares in Hong Kong
- pixelgrinder Announces Second Full-Length Album “White Mask” for September 25 Release
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Chardan Capital MarketsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share